Sicam-1, sCD95 and sCD95L Levels in Chronic Liver Diseases of Different Etiology

References

• Fiore G., Angarano I., Caccetta L., Serrone M., Jirillo E., Schiraldi O., Antonaci S. In-situ immunophenotyping study of hepatic-infiltrating cells in chronic active hepatitis C. Eur. J. Hepatol. Gastroenterol. 1997; 9: 491
   PubMed Web of Science ®Google Scholar
• Khakoo S. I., Soni P. N., Savage K., Brown D., Dhillon A. P., Poulter L. W., Dusheiko G. M. Lymphocyte and macrophage phenotypes in chronic hepatitis C infection. Correlation with disease activity. Am. J. Pathol. 1997; 150: 963
   PubMed Web of Science ®Google Scholar
• Simpson K. J., Hayes P. C. Soluble adhesion molecules in immune mediated liver diseases. Gut 1995; 36: 806
   PubMedGoogle Scholar
• Bach N., Thung S. N., Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992; 15: 572
   PubMed Web of Science ®Google Scholar
• Spengler U., Leifeld L., Braunschweiger I., Dumoulin F. L., Lechmann M., Sauerbruch T. Anomalous expression of costimulatory molecules B7–1, B7–2 and CD28 in primary biliary cirrhosis. J. Hepatol. 1997; 26: 31
   PubMedGoogle Scholar
• Chedid A, Mendenhall C. L., Moritz T. E., French S. W., Chen T. S., Morgan T. R., Roselle G. A., Nemchausky B. A, Tamburro C. H., Schiff E. R., McClain C. J., Marsano L. S., Allen J. I., Samanta A., Weesner R. E., Henderson W. G. and Veterans Affairs Cooperative Study Group 275, Cellmediated injury in alcoholic liver disease. Gastroenterology 1993; 105: 254
   PubMed Web of Science ®Google Scholar
• Higaki K., Yano H., Kojiro M. Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissue. Am. J. Pathol. 1996; 149: 429
   PubMed Web of Science ®Google Scholar
• Patel T., Gores G. J. Apoptosis and hepatobiliary disease. Hepatology 1995; 21: 1725
   PubMed Web of Science ®Google Scholar
• Galle P. R., Krammer P. H. CD95-induced apoptosis in human liver disease. Semin. Liver Dis. 1998; 18: 141
   PubMedGoogle Scholar
• Antonaci S., Schiraldi O. Costimulatory molecules and cytotoxic T cells in chronic hepatitis C: defence mechanisms devoted to host integrity or harmful events favouring liver injury progression? A review. Immunopharmacol. Immunotoxicol. 1998; 20: 455
   PubMed Web of Science ®Google Scholar
• Mariani S. M., Matiba B., Baumler C., Krammer P. H. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol. 1995; 25: 2303
   PubMed Web of Science ®Google Scholar
• Cascino I., Fucci G., Papoff G., Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol. 1995; 154: 2706
   PubMed Web of Science ®Google Scholar
• Tanaka M., Suda T., Haze K., Nakamura N., Sato K., Kimura F., Motoyoshi K., Mizuki M., Tagawa S., Ohga S., Hatake K., Drummond A. H., Nagata S. Fas ligand in human serum. Nat. Med. 1996; 2: 317
   PubMed Web of Science ®Google Scholar
• Kaplanski G., Famarier C., Payan M. J., Bongrand P., Durand J. M. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentrations and liver inflammation and fibrosis. Dig. Dis. Sci. 1997; 42: 2277
   PubMedGoogle Scholar
• Piazzolla G., Tortorella C., Fiore G., Serrone M., Caccetta L., Jirillo E., Schiraldi O., Antonaci S. Immunoresponsiveness in Chronic Hepatitis C patients: correlation between tissue and serum findings. Immunopharmacol. Immunotoxicol. 1998; 20: 337
   PubMed Web of Science ®Google Scholar
• Simpson K. J., Jones A. L., Forbes Howie A., Hayes P. C. Soluble adhesion molecules and interleukin-2 receptor concentrations in patients with autoimmune chronic hepatitis. Eur. J. Gastroenterol. Hepatol. 1995; 7: 455
   PubMed Web of Science ®Google Scholar
• Lim A. G., Jazrawi R. P., Ahmed H A, Levy J. H., Zuin M., Douds A. C., Maxwell J. D., Northfield T. C. Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: relationship with disease stage, immune activity and cholestasis. Hepatology 1994; 20: 882
   PubMedGoogle Scholar
• Douds A. C., Lim A. G., Jazrawi R. P., Finlayson C., Maxwell J. D. Serum intercellular adhesion molecule-1 in alcoholic liver disease and its relationship with histological disease severity. J. Hepatol. 1997; 26: 280
   PubMedGoogle Scholar
• Shimizu Y., Minemura M., Tsukishiro T., Kashii Y., Miyamoto M., Nishimori H., Higuchi K., Watanabe A. Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis. Hepatology 1995; 22: 525
   PubMedGoogle Scholar
• Johnson P. J., McFarlane I. G. Meeting report: International autoimmune hepatitis group. Hepatology 1993; 18: 998
   PubMed Web of Science ®Google Scholar
• International Group, Alcoholic liver disease. morphological manifestations. Lancet 1981; 1: 707
   PubMedGoogle Scholar
• Rothlein R., Mainolfi E., Czajkowski M., Marlin S. D. A form of circulating ICAM-1 in human serum. J. Immunol. 1991; 147: 3788
   PubMed Web of Science ®Google Scholar
• Volpes R., Van Der Oord J. J., Desmet V. J. Immunohistochemical study of adhesion molecules in liver inflammation. Hepatology 1990; 12: 59
   PubMed Web of Science ®Google Scholar
• Volpes R., Van Der Oord J. J., Desmet V. J. Vascular adhesion molecules in acute and chronic liver inflammation. Hepatology 1992; 15: 269
   PubMed Web of Science ®Google Scholar
• Lim A. G., Wolfhagen H. J., Verma A., Van Buuren H. R., Jazrawi R. P., Levy J. H., Northfield T. C., Schalm S. W. Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: effect of ursodeoxycholic acid and immunosuppressive therapy. Eur. J. Gastroenterol. Hepatol. 1997; 9: 155
   PubMedGoogle Scholar
• Soresi M., Cervello M., Lipani G., Carroccio A., Cartabellotta A., Marasa L., Casto C., Virruso L., Montalto G. Circulating intercellular adhesion molecule-1 in patients with hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 1997; 9: 805
   PubMedGoogle Scholar
• Pirisi M., Falletti E., Fabris C., Soardo G., Toniutto P., Vitulli D., Pezzetta F., Bortolotti N., Gonano F., Bartoli E. Circulating intercellular adhesion molecule-1 (cICAM-1) concentration in liver disease. Relationship with cholestasis and functioning hepatic mass. Am. J. Clin. Pathol. 1994; 102: 600
   PubMedGoogle Scholar
• Luna-Casado L., Diez-Ruiz A., Gutierrez-Gea F., Santos-Perez J. L., Rico-Irles J., Wachter H., Fuchs D. Increased peripheral mononuclear cells expression of adhesion molecules in alcoholic cirrhosis: its relation to immune activation. J. Hepatol. 1997; 27: 477
   PubMed Web of Science ®Google Scholar
• Cheng J., Zhou T., Liu C., Shapiro J. P., Brauer M. J., Kiefer M. C., Barr P. J., Mountz J. D. Protection from Fas-mediated apoptosis by soluble form of the Fas molecule. Science 1994; 263: 1759
   PubMed Web of Science ®Google Scholar
• Lio S., Hayashi N., Mita E., Ueda K., Mochizuki K., Hiramatsu N., Kanto T., Sasaki Y., Kasahara A., Hori M. Serum levels of soluble Fas antigen in chronic hepatitis C patients. J. Hepatol. 1998; 29: 517
   PubMedGoogle Scholar
• Fiore G., Piazzolla G., Galetta V., Caccetta L., Schiraldi O., Antonaci S. Liver tissue expression of CD80 and CD95 antigens in chronic hepatitis C: relationship with biological and histological disease activities. Microbios 1999; 97: 29
   PubMedGoogle Scholar
• Galle P. R., Hofmann W. J., Walczak H., Schaller H., Otto G., Stremmel W., Krammer K., Runkel L. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 1995; 182: 1223
   PubMed Web of Science ®Google Scholar
• Jodo S., Kobayashi S., Nakajima Y., Matsunaga T., Nakayama N., Ogura N., Kayagaki N., Okumura K., Koike T. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin. Exp. Immunol. 1998; 112: 166
   PubMed Web of Science ®Google Scholar
• Strand S., Hofmann W. J., Hug H., Muller M., Otto G., Strand D., Mariani S. M., Stremmel W., Krammer P. H., Galle P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion?. Nat. Med. 1996; 2: 1361
   PubMed Web of Science ®Google Scholar
• O'Connel J., Bennet M. W., O'Sullivan G. C., Collins J. K., Shanahan F. The Fas counterattack: cancer as a site of immune privilege, Immunol. today 1999; 20: 46
   Google Scholar